申请人:Hoffmann-La Roche Inc.
公开号:US05385947A1
公开(公告)日:1995-01-31
Compounds of the formula: ##STR1## wherein R.sup.1 and R.sup.2 each individually are hydrogen or lower alkyl optionally substituted by aryl or C.sub.3-6 -cycloalkyl; R.sup.4 and R.sup.5 either both are hydrogen or both are halogen or one is hydrogen and the other is halogen, hydroxy, lower alkoxy, aryloxy or amino; and R.sup.3 is hydrogen or, where no primary or secondary amino group is present, alkanoyl; with the proviso that all the groups R.sup.1 through R.sup.5 cannot simultaneously be hydrogen; as well as pharmaceutically acceptable salts of compounds of formula I with acids have valuable pharmacodynamic properties as non-competitive NMDA antagonists and can accordingly be used as neuroprotectives.
具有以下结构的化合物:##STR1## 其中R.sup.1和R.sup.2各自为氢或辅以芳基或C.sub.3-6-环烷基的低烷基; R.sup.4和R.sup.5要么都是氢,要么都是卤素,或者一个是氢另一个是卤素、羟基、低烷氧基、芳氧基或氨基; R.sup.3是氢或者在没有一级或二级氨基团的情况下是烷酰基; 但是要注意,所有的基团R.sup.1到R.sup.5不能同时为氢;以及具有药用酸盐的I式化合物具有有价值的药理作用性质,作为非竞争性NMDA拮抗剂,并因此可用作神经保护剂。